Strensiq Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved recognition of hypophosphatasia, availability of orphan drug incentives, clinical validation of enzyme replacement therapies, expansion of genetic testing programs, increased physician awareness.

The growth in the forecast period can be attributed to increasing adoption in adult-onset hpp patients, expansion of rare disease treatment access, rising investment in orphan drug pipelines, growing focus on home-based therapy administration, continued development of personalized treatment approaches. Major trends in the forecast period include increasing focus on enzyme replacement therapies, rising diagnosis rates of rare bone disorders, expansion of long-term treatment protocols, growing use of subcutaneous administration, enhanced patient monitoring and adherence programs.

The increasing emphasis on rare disease treatments is expected to drive the growth of the Strensiq market in the future. Rare disease treatment refers to medical interventions specifically designed to address conditions that affect a small percentage of the population, often involving specialized therapies or medications that may not be widely available. The growing focus on rare disease treatment is driven by factors such as precision medicine, unmet patient needs, regulatory incentives, and opportunities for innovation in healthcare. Strensiq, an enzyme replacement therapy, plays a critical role in treating hypophosphatasia, a rare genetic disorder that affects bone mineralization. By replenishing the deficient alkaline phosphatase enzyme, Strensiq improves bone health, reduces skeletal abnormalities, and enhances the overall quality of life for patients with this debilitating condition. For example, in October 2024, a report from the Cystic Fibrosis Trust, a UK-based non-profit organization, revealed that the number of people registered with cystic fibrosis (CF) in the UK surpassed 11,318 in 2023. Additionally, 63.7% of individuals with CF in the UK are over 16 years of age, and 16.7% are over 40. As a result, the growing focus on rare disease treatment is fueling the growth of the Strensiq market.

The growing focus on personalized medicine is expected to accelerate the growth of the Strensiq market moving forward. Personalized medicine is a healthcare approach that tailors treatment and strategies to the unique characteristics of each patient. This approach is gaining momentum as it customizes therapies based on an individual’s genetic profile, lifestyle, and environment, thereby enhancing the effectiveness of treatments and minimizing side effects. Strensiq supports personalized medicine by offering targeted enzyme replacement therapy for patients with hypophosphatasia, a rare genetic disorder. This allows for customized treatment plans that address specific genetic mutations and the varying severity of the disease in each patient, leading to improved outcomes and a better quality of life. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from just six in 2022. As a result, the increasing focus on personalized medicine is driving the growth of the Strensiq market.

The rise in healthcare expenditures is also expected to drive the growth of the Strensiq market. Healthcare expenditures include all costs associated with providing health services, family planning activities, nutrition programs, and emergency care, with a focus on health. These expenditures are rising as more stakeholders prioritize advanced therapies and better patient outcomes, resulting in increased spending on specialized medical care. Strensiq plays an important role in the rise of healthcare expenditures by providing enzyme replacement therapy for hypophosphatasia, improving patient outcomes, and driving demand for specialized treatments. For instance, in May 2023, the Office for National Statistics, a UK-based authority, reported that healthcare expenditure in the UK was approximately $362.08 billion (£292 billion) in 2023, reflecting a nominal increase of 5.6%. Additionally, healthcare spending as a percentage of gross domestic product (GDP) decreased slightly to 10.9% in 2023 from 11.1% in 2022. Therefore, the rising healthcare expenditures are contributing to the growth of the Strensiq market.

Major companies operating in the strensiq market are AstraZeneca plc.

North America was the largest region in the strensiq market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strensiq market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the strensiq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the strensiq market by increasing costs of imported recombinant enzymes, specialized formulation materials, cold-chain logistics solutions, and single-use injection devices. Rare disease treatment providers in North America and Europe are most affected due to reliance on globally sourced biologic inputs, while Asia-Pacific faces challenges in import-dependent specialty drug distribution. These tariffs are increasing therapy costs and affecting reimbursement negotiations. However, they are also promoting regional biologics manufacturing, localized packaging operations, and stronger domestic supply chains for orphan drugs.

The strensiq market research report is one of a series of new reports that provides strensiq market statistics, including strensiq industry global market size, regional shares, competitors with a strensiq market share, detailed strensiq market segments, market trends and opportunities, and any further data you may need to thrive in the strensiq industry. This strensiq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Strensiq is a prescription medication that contains asfotase alfa, a targeted enzyme replacement therapy designed specifically for the treatment of hypophosphatasia (HPP). It is administered as a subcutaneous injection several times a week to replace the deficient enzyme in patients with hypophosphatasia, thereby improving bone mineralization and supporting overall skeletal health.

The primary formulations of Strensiq include subcutaneous injection and single-use vials. Subcutaneous injection refers to the method of administering the medication directly into the layer of fat and tissue just beneath the skin. This method is used for various clinical indications, including perinatal or neonatal-onset HPP, infantile-onset HPP, childhood-onset HPP, and adult-onset HPP. The medication is distributed through retail and online pharmacies, catering to both pediatric and adult end users.

The strensiq market consists of sales of subcutaneous injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.